An acidic domain (AD) of gp130 was previously found to interact with the Src family kinase (SFK) Hck. Here, the influence of myristoylated peptides derived from this AD was assessed in the mouse myeloma cell line, 7TD1. The IL-6-dependent growth of 7TD1 cells was reduced by B75%, if 100 lM of myristoylated 18mer peptide (18AD) was included in the growth medium, but was unaffected by a control peptide with scrambled sequence (18sc). A similar differential inhibition by peptides 18AD and 18sc was observed for the erythropoietin-dependent growth of BaF-EH cells expressing chimeric erythropoietin receptor-gp130 and human Hck and for the human myeloma cell line INA-6. While the peptide 18AD concentration inhibiting 50% was B30 lM in 7TD1 and BaF-EH cells, peptide 18AD did not significantly inhibit growth of IL-6-independent MM1.S myeloma and OKT1 hybridoma cells or of BaF-EH cells supplied with IL-3. Treatment with 100 lM peptide 18AD caused the same degree or 60% of apoptosis induction as IL-6 deprivation in 7TD1 or INA-6 cells, respectively. Co-immunoprecipitation experiments revealed that peptide 18AD interfered with the association of Hck and gp130 in 7TD1 lysates in a concentrationdependent manner. IL-6-treatment of INA-6 cells induced the kinase activities of Fyn, Lyn and Hck, but not Src, and the IL-6-induced SFK activities were inhibited by peptide 18AD. Expression in 7TD1 cells of a kinaseinactive Hck mutant (K269R) elicited a dominantnegative effect on cell number increases providing further evidence that SFKs are required for gp130 signalling in myeloma cells.
Introduction
The role of the multifunctional cytokine interleukin-6 (IL-6) (Ishihara and Hirano, 2002) as the major growth factor for multiple myeloma (MM) cells is supported by clinical data, transgenic mouse models and signalling studies (Hallek et al., 1998) . Recently stimulation of myeloma cells with IL-6 was found to induce the expression of genes implicated in cell growth and the prevention of apoptosis (French et al., 2000; Cote et al., 2002; Brocke-Heidrich et al., 2004) . As the proliferation of myeloma cells appears to be supported by IL-6 during most stages of the disease (Hideshima and Anderson, 2002) , therapeutic approaches preventing engagement of the IL-6 receptor include antibodies against IL-6 (Trikha et al., 2003) , IL-6 peptide antagonists (Manfredini et al., 2003) and soluble IL-6 receptors that serve as cytokine traps (Ancey et al., 2003) .
Signalling from the hexameric IL-6 receptor (IL-6R) complex requires the recruitment of cytoplasmic tyrosine kinases and proceeds via at least two major pathways: the Janus kinases/signal transducers and activators of transcription (JAK/STAT) pathway (Stahl et al., 1994; Ihle, 1996) and the Ras/(mitogen-activated protein kinase) MAPK signalling cascade (Neumann et al., 1996; Hallek et al., 1997; Ogata et al., 1997) . Recent in vivo studies have shown that gp130-mediated signals were regulated by a balance between these two pathways (Ohtani et al., 2000; Heinrich et al., 2003; Ernst and Jenkins, 2004) . There is evidence, however, that only activation of the ras/MAPK signalling cascade correlates with the proliferation response of MM cells to IL-6. Jak and STAT proteins are activated by IL-6 in MM cells, but do not lead to concomitant proliferation (Hallek et al., 1998) . In co-cultures of MM cells with bone marrow stromal cells the ras/MAPK pathway prevails over the Jak/STAT pathway (Chatterjee et al., 2002) .
The Src family kinase (SFK) Hck is associated with the IL-6R b-chain, gp130, (Ernst et al., 1994) , and by demonstrating IL-6-induced Hck activation we have identified SFKs as potential intracellular targets for blocking IL-6 signalling. Recently, we were able to map the Hck-binding region of gp130 to positions 771-811 (Schaeffer et al., 2001) . This region was termed acidic domain (AD) owing to its high content of acidic residues, in analogy with the acidic region of the IL-2Rb subunit for interaction with the SFK p56 lck (Hatakeyama et al., 1991) . We aimed to refine the Hck-binding site on gp130 by employing a set of membrane-permeant peptides, representing overlapping fragments of the AD, which were made membranepermeant by conjugation with myristate.
We used the mouse hybridoma cell line 7TD1 to characterize the effect of myristoylated peptide sequences on the IL-6-dependent cell number increase. After identification of the inhibitory peptide 18AD, we aimed at uncovering the underlying mechanisms and investigated whether peptide 18AD disrupted the co-immunoprecipitation (co-IP) of gp130 and Hck. For analysis of gp130-mediated signalling pathways, we determined the influence of heterologously expressed mutants of human Hck on the IL-6-dependence of 7TD1-derived recombinant cell lines and monitored IL-6-induced STAT3-phosphorylation. To exclude that the observed effects of peptide 18AD on cell growth and survival were restricted to 7TD1 cells, the mouse pro-B cell line Ba/F3 expressing chimeric erythropoietin receptor (EpoR)-gp130 and human Hck (Schaeffer et al., 2001) and the human myeloma cell lines INA-6 (Burger et al., 2001 ) and MM1.S (Greenstein et al., 2003) were employed as additional model systems. In IL-6-dependent INA-6 cells, we investigated the effects of peptide 18AD on IL-6-induced activation of the SFKs Hck, Lyn, Fyn and Src. Although further investigations of the downstream signalling cascades are needed, our study describes a peptide inhibitor of IL-6-dependent myeloma growth and provides first evidence for the involvement of SFKs in its mechanism of action.
Results
Inhibition of IL-6-induced proliferation of 7TD1 cells by a myristoylated gp130-derived 18mer peptide To find out the minimal intracellular domain of gp130, that is required for the interaction with SFKs and for the transduction of proliferation signals, a peptide-based functional screening assay was used to detect effects on growth and survival of 7TD1 cells. For this purpose, a set of four overlapping peptides was derived from the previously defined 41 aa Hck-binding region ( Figure 1a) . The peptide sequences were chemically synthesized with a myristoyl moiety attached to their N-termini in order to enable them to cross cell membranes. Their capability to inhibit IL-6-dependent growth of 7TD1 cells was monitored by observing the cell densities reached in the presence of 40 pg IL-6/ml and after addition of 50 or 100 mM of the individual peptide sequences (Figure 1b) . Among the tested peptides, the 18mer sequence of P3 comprising aa 783-800 of gp130 showed the biggest inhibitory effect at both peptide doses. Therefore P3, that contained six acidic residues, was selected for further studies and termed peptide 18AD. To determine the specific role of the sequence context, a myristoylated peptide with an identical aa composition but arbitrarily scrambled sequence, peptide 18sc, which was expected to have similar physicochemical properties, was used as a control (Figure 1c ). The effects of both peptides on 7TD1 cells were compared. In the presence of 100 mM of peptide 18AD, 7TD1 cells stimulated with IL-6 attained only about 25% of the cell densities obtained with IL-6 alone or in the presence of the control peptide 18sc (Figure 1d ).
Cellular uptake of myristoylated peptide Cellular uptake of the tested peptide sequences is a prerequisite for their efficacy in influencing intracellular events. The wide use of acylation in general for peptide delivery (Adachi et al., 1999b; Boehning et al., 2005) and of myristoylation in particular (Eichholtz et al., 1993; Kelemen et al., 2002; Niv et al., 2004) made it likely that also the present peptides entered into the cytoplasm. To confirm this assumption, 100 mM of fluorescence-labelled derivatives of peptide 18AD and its non-myristoylated equivalent were added to suspensions of 7TD1 cells. During flow-cytometric analysis virtually all viable cells treated with fluoresceine-labelled peptide 18AD were stained with the label, whereas only B5% exhibited fluorescence after treatment with Cy5-labeled peptide 18ADnm ( Figure 2a ). Despite thorough washing, staining of 7TD1 cells by fluorescein-labelled peptide 18AD may also be explained by myristoylated peptide attaching to the outer side of the plasma membrane. However, an equal concentration of peptide 18ADnm did not result in the growth inhibition found with peptide 18AD (Figure 2b ), proving that only the myristoylated form is taken up into the cytoplasm.
Specificity of the inhibition of gp130-dependent cell growth by peptide 18AD The effects of peptide 18AD on the IL-6-dependent growth of 7TD1 cells and on an IL-6-independent mouse hybridoma cell line, OKT1, were compared ( Figure 2b ). IL-6-dependent growth of 7TD1 cells was inhibited by peptide 18AD, but neither by the 18sc or 18ADnm control peptides. In contrast, the growth of OKT1 cells was not affected by any of the tested peptides. As the concept of an Hck-binding region had been derived from observations of cloned chimeric EpoRgp130 (Schaeffer et al., 2001) , the impact of peptides 18AD and 18sc on Ba/F3 cells overexpressing Hck and EpoR-gp130 was investigated. Ba/F3 cells grow IL-3 dependently and growth induction by Epo was observed in the genetically engineered derivative cell line, BaF-EH, but not in the parent cell line. Peptide 18AD inhibited erythropoietin-dependent growth of BaF-EH cells, whereas their IL-3-dependent growth was not significantly influenced by peptide 18AD (Figure 2c ).
Impact of peptide 18AD on IL-6-dependent growth of murine and human myeloma cells With view to potential therapeutic applications of peptide 18AD in humans, the growth kinetics of 7TD1 cells with and without IL-6 and in the presence of peptides 18AD and 18sc were compared with those of the human myeloma cell lines, INA-6 and MM1.S (Figure 3) . While 7TD1 and INA-6 cells are IL-6-dependent, MM1.S cells grow independently of growth factors. In both IL-6-dependent cell lines, the cell numbers, which were not influenced by peptide 18sc, were reduced relative to control cultures by IL-6 withdrawal and treatment with peptide 18AD, with slightly stronger inhibition by 100 mM peptide 18AD in INA-6 as compared to 7TD1 cells. In 7TD1 cells, the inhibition of viable cell number increase due to IL-6 deprivation or to treatment with peptide 18AD was of similar size, while in INA-6 cells, the effect of IL-6 withdrawal surpassed that of peptide 18AD addition and resulted in a net reduction of viable cell numbers. The growth kinetics of IL-6-independent MM1.S cells were not affected by any of the tested peptides nor by IL-6 deprivation (Figure 3c ).
Peptide 18AD inhibited IL-6-dependent growth of 7TD1 cells with an apparent concentration inhibiting 50 Proliferation inhibition by a gp130-derived peptide A Hausherr et al
Cell cycle phase profiles in the absence or presence of IL-6 and after treatment with 50 mM of peptides 18AD and 18sc were compiled by analysing the cellular DNA content of 7TD1 and INA-6 cells. A significant proportion of IL-6-deprived cells were arrested at the G1-phase (Figure 5c ). Addition of peptides 18AD or 18sc in the presence of IL-6 did not lead to any significant changes of the distribution of cell cycle phases (Figure 5d ).
Association of gp130 and Hck in 7TD1 cells
To investigate the mechanism of action of peptide 18AD, the effect of IL-6 stimulation and of the addition of 100 mM of peptide 18AD or 18ADnm on the association of gp130 and Hck was examined at native expression levels in 7TD1 cells (Figure 6a ). Co-IP of gp130 with Hck was hardly detectable in starved 7TD1 cells, but gp130 was co-precipitated upon addition of 1 ng IL-6/ml for 15 min before lysis. If added to IL-6-stimulated 7TD1 cells, peptide 18AD reduced the co-IP signal, whereas peptide 18ADnm had no effect. The lack of disruption of the Hck-gp130-association by peptide 18ADnm added to intact cells is in agreement with the differential peptide uptake (Figure 2a ) and efficacy (Figure 2b ) of the non-myristoylated versus the myristoylated version. When added to 7TD1 lysates, peptide 18ADnm was more efficient in reducing co-IP signals than peptide 18AD and therefore was used to assess, which peptide concentrations were necessary for displacing Hck from gp130 (Figure 5b ). At concentrations above 50 mM, addition of peptide 18ADnm to lysates of IL-6 treated 7TD1 cells clearly inhibited the coprecipitation of gp130 with Hck. To enhance the evidence for the disruption of Hck-gp130 binding, we applied 293 cells as a transient transfection system affording higher expression levels of the binding partners ( Figure 5c ). In contrast to IL-6 stimulation in 7TD1 cells, addition of 10 U Epo/ml for 15 min did not increase the binding of Hck and EpoR-gp130. At a concentration of 750 mM, peptide 18AD disrupted the association of overexpressed Hck and EpoR-gp130, which was not disturbed by peptide 18sc. Affinity pulldowns from 293 lysates containing overexpressed human Hck were performed using streptavidin beads and chemically synthesized biotinylated peptides 18AD, 18sc and a SH2-binding peptide (Figure 5d ). Peptide 18AD-bio and the positive control peptide SH2-bio picked up greater amounts of Hck than peptide 18sc-bio or control assays without peptide, confirming the binding of peptide 18AD to Hck. Apart from disturbance by addition of peptide 18AD, the association of Hck and EpoR-gp130, that were transiently expressed in COS7 Proliferation inhibition by a gp130-derived peptide A Hausherr et al 8 aa, but not of the 18 aa corresponding to peptide 18AD, possibly due to technical difficulties (not shown).
Impact of peptide 18AD on IL-6-induced SFK activity and STAT3 phosphorylation To investigate the mechanisms, by which peptide 18AD inhibits gp130-mediated proliferation and survival signalling, activation of the SFKs Hck, Lyn, Fyn and c-Src upon IL-6 stimulation and its modulation by 100 mM of peptides 18AD and 18sc was assessed in INA-6 lysates by immunocomplex kinase assays (Figure 7a ). Hck, Lyn and Fyn exhibited IL-6-induced autophosphorylation of the kinases, which was reduced in the presence of peptide 18AD but not peptide 18sc. Activation of the same SFKs and its inhibition by peptide 18AD was also indicated by the phosphorylation levels of the externally added kinase substrate enolase. In contrast, IL-6 stimulation did not increase the kinase activity of c-Src (Figure 7a ). For assessing the influence of peptide 18AD on the JAK/STAT mediated IL-6 signalling pathway, the phosphorylation status of tyrosine 705 in STAT3 was analysed in 7TD1 cells. While STAT3 phosphorylation was induced by IL-6 treatment of 7TD1 cells, it was not reduced by the further addition of peptide 18AD (Figure 7b) .
Influence of the expression of Hck variants on the IL-6-dependent growth of 7TD1 cells To demonstrate the role of SFK for IL-6-signalling in 7TD1 cells, wild type (wt) or constitutively active (Y501F) or inactive mutants (K269R) of human Hck were transduced into 7TD1 cells, which express native levels of mouse Hck. Sorted, polyclonal cell populations Proliferation inhibition by a gp130-derived peptide A Hausherr et al were examined in proliferation assays using several doses of IL-6 in order to investigate the influence of overexpressed Hck mutants on IL-6-dependence ( Figure 8a ). The IL-6 requirement of 7TD1/Hck-Y501F cells could not be distinguished from that of controls expressing GFP alone. The cell densities of 7TD1/Hck-K269R in response to IL-6 reached a threshold at about 6 Â 10 5 cells per ml, while cells expressing GFP alone or together with Hck-Y501F grew up to densities of 10 6 cells per ml. Thus, proliferation of 7TD1/Hck-K269R cells in response to IL-6 was decreased compared to the controls, demonstrating that an excess of transduced kinase-inactive Hck disturbed the contribution of intrinsic mouse Hck to the IL-6-dependent growth of 7TD1 cells.
Despite equal GFP expression, about fourfold lower expression of the human Hck-Y501F or Hck-wt gene products was detected on Western blots than of the correspondent kinase-inactive mutant (Figure 8b ). This difference in expression levels, however, does not affect the conclusion of dominant-negative effects, since the changes occurred relative to controls expressing either only intrinsic mouse Hck or additionally human catalytically active Hck.
As addition of peptide 18AD and the expression of inactive Hck both inhibit the IL-6-dependent increase of 7TD1 cell numbers, we observed the combined effect of these treatments on cell numbers in order to determine the role of SFK activity in IL-6-mediated survival signalling and its inhibition by peptide 18AD (Figure 8c ). The cell numbers attained by 7TD1 cells expressing Hck-K269R or treated with peptide 18AD in the presence of IL-6 were significantly lower than those of cells expressing GFP only treated with peptide 18sc. In cells expressing catalytically inactive Hck, treatment with peptide 18AD did not lead to a significant further reduction of cell numbers, demonstrating a considerable contribution of SFK activity to the inhibitory mechanism of peptide 18AD.
To further investigate the role of Hck in IL-6 signalling, we compared the tyrosine phosphorylation profiles in retrovirus-transduced 7TD1 cells expressing GFP alone or additionally Hck-wt or Hck-K269R (Figure 8d) . Following IP by two anti-pY-antibodies and immunodetection by a third directly labelled antipY-antibody, increases of the tyrosine phosphorylation intensities during one and five minutes of IL-6 treatment were considerably weaker in the 7TD1 derivative expressing Hck-K269R, confirming the dominant-negative effect of the catalytically inactive Hck mutant. STAT3 phosphorylation was induced upon IL-6 addition to 7TD1 cells independently of additional overexpressed Hck-K269R, which is in line with our observation that peptide 18AD did not disturb the induction of STAT3 phosphorylation upon IL-6 induction ( Figure 7b ).
Discussion
An N-terminally myristoylated peptide 18AD, the sequence of which was derived from an Hck-binding and -activating region of gp130, specifically inhibited IL-6-dependent proliferation of MM cells. The relevance and specificity of the growth inhibition observed in the IL-6-dependent mouse hybridoma cell line 7TD1 was supported by the following evidence. (1) In order to exclude the impact of the considerable load of myristoylated peptide containing a high percentage of acidic side chains, all experiments were accompanied by a control using an arbitrarily scrambled peptide sequence (Figures 1c and d, 2b, 3 and 4) . (2) Myristoylated peptides actually reached their intracellular site of action, as evidenced by selective staining of target cells by fluorescence-labelled peptide 18AD, but not by its non-myristoylated equivalent (Figure 2a) , and their inhibitory action on factor-dependent growth of 7TD1 (Figure 2b) or Baf-EH cells (Figure 2c ) depended on the myristoyl modification. (3) The effects of peptide 18AD on 7TD1 cells were reproduced in the IL-6-dependent human myeloma cell line, INA-6, and in BaF-EH cells overexpressing Hck and chimeric EpoR-gp130. As the response of Baf-EH cells to Epo was due to overexpressed EpoR-gp130 and Hck molecules, inhibition by peptide 18AD of Epo-dependent proliferation (Figures 2c and 4c) proved that peptide 18AD interrupted survival signals involving these proteins. (4) Unspecific cytotoxic effects of peptide 18AD were exluded by the lack of growth inhibition in the IL-6-independent cell lines OKT1 (Figure 2b ) and MM1.S (Figure 3c ). In addition, peptide 18AD did not influence IL-3-dependent growth of wt or genetically engineered Ba/F3 cells significantly more than the control peptide 18sc (Figure 4a ). 
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The effects of peptide 18AD on myeloma cells were further characterized by assessing growth kinetics (Figure 3) , apoptosis induction and distribution of cell cycle phases ( Figure 5 ). For potential clinical applications it is important to note that the inhibition of IL-6-dependent proliferation by peptide 18AD was even stronger in the human myeloma cell line, INA-6, than in 7TD1 cells. The bigger effect of IL-6 withdrawal on all three tested read-outs in INA-6 as compared to 7TD1 cells may be due to the 10 times higher IL-6 requirement of INA-6 cells (Burger et al., 2001) . Apoptosis induction by peptide 18AD appears to be the prevalent contribution to the IL-6-dependent increase in cell number, since inhibition of cell cycle progression by peptide treatment could not be detected ( Figure 5 ). On the other hand, the distribution of cell cycle phases was only moderately changed by IL-6 deprivation. Proliferation must, however, play a role for the balance between cell division and cell death, since the overall cell numbers still increase in the presence of peptide 18AD.
The potentially therapeutically important inhibition of IL-6-dependent cell growth by peptide 18AD needed to be reaffirmed by mechanistic observations on the level of protein association in order to prove our starting assumption that peptide 18AD blocks the binding of Hck and gp130. As a first prerequisite for disrupting intracellular protein-protein interactions, which are for example important for G protein-coupled receptor signalling, the active peptides, for example so-called pepducins (Covic et al., 2002) , must be taken up into the cytoplasm, which in our case was achieved by conjugation with the fatty acid myristate, that is a common modification of SFK. As a next step, we were able to show binding of Hck to gp130 and its displacement by peptide 18AD by co-IP in 7TD1 cells ( Figure 6 ). As co-IP was performed at native expression levels, coprecipitation signals upon IL-6 stimulation were weak, but clearly further reduced upon addition of peptide 18ADnm to lysates or of peptide 18AD to intact cells (Figure 6a ). The lack of disruption of the Hckgp130 complex by peptide 18AD added to lysates may be explained by altered distribution and accessibility of the myristoylated peptide in lysates containing traces of detergent. The minimal dose of peptide 18ADnm Proliferation inhibition by a gp130-derived peptide A Hausherr et al required for disrupting the association of gp130 and Hck was B50 mM (Figure 6b ), whereas often peptide concentrations of 20 mM and below were sufficient for displacing proteins from associations (Adachi et al., 1999a, b; Kardinal et al., 2000; Boehning et al., 2005) , although up to 1 mM was used for disrupting pre-existing complexes (Posern et al., 1998) . The association of Hck and gp130 and its interruption by peptide 18AD were confirmed by peptide competition and affinity pull-down analyses using overexpression of the involved proteins and applying a peptide concentration of 750 mM (Figure 6c, d) . At native expression levels peptide 18AD effects were more clearly detected in proliferation assays than in co-IP experiments confirming the suitability of a functional assay for the initial characterization, but leaving a discrepancy in the size of peptide effects between displacement of Hck from gp130 and growth inhibition. The requirement of additional docking proteins and the distribution of participating molecules in membrane microdomains (Podar et al., 2003 (Podar et al., , 2004 may enhance peptide 18AD effects on cell number as compared to association of certain proteins.
With an IC 50 of B30 mM in the 7TD1 and BaF-EH cell culture models peptide 18AD appears comparable to other inhibitory peptides. Thus, the full apoptosis induction in 7TD1 cells by the IL-6-antagonistic peptide RGKEELD was achieved by concentrations above 30 mM (Manfredini et al., 2003) . For myristoylated peptides derived from the catalytic domains of different protein kinases and used at a concentration of 10 mM, the threshold for a proof of efficacy against cancer cell lines was set at 40% growth inhibition (Niv et al., 2004) . The inhibition of Erk phosphorylation by membranepenetrating MEK1-derived peptides exhibited IC 50 -values of 10-30 mM (Kelemen et al., 2002) . In contrast, inhibition by the somatostatin analogs octreotide or RC-160 of the proliferation of myeloma cell lines (Georgii-Hemming et al., 1999) , or a human oral carcinoma cell line (Dasgupta et al., 2000) , respectively, occurred in the nM concentration range, and the latter peptide was more potent when myristoylated. Also the displacement of cytochrome C from IP3-receptor and caspase inhibition by a BODIPY-conjugated acidic peptide occurred with IC 50 in the nM range (Boehning et al., 2005) .
Membrane-associated SFKs are known to mediate proliferation and survival signals from a variety of cytokine receptors, for example p56 lck from the IL-2 receptor (Hatakeyama et al., 1991) . In a similar manner, the SFK Hck was shown to be associated with the AD of gp130 (Schaeffer et al., 2001) , the central portion of which shows some similarity to consensus substrate sequences of protein tyrosine kinases, although it does not contain a tyrosine. In MM cell lines IL-6 stimulation increases the activity of Fyn, Hck and Lyn , as was confirmed here for INA-6 cells, where the IL-6 induced activation was inhibited by peptide 18AD (Figure 7a) . Thus, the anti-proliferative and proapoptotic effects of peptide 18AD can be explained by disruption of gp130-SFK associations and inhibition of SFK activity. In contrast, the alternative JAK/STATmediated IL-6-signalling pathway was not inhibited by peptide 18AD (Figure 7b ) or catalytically inactive Hck (Figure 8d ) as evidenced by the STAT3 phosphorylation status. Recently, an important role of Hck for survival signalling in MM cells was found to consist in mediating the phosphorylation of the docking proteins Gab1 and Gab2 (Podar et al., 2004) . In epithelial cells devoid of SFK activity, however, signal transduction pathways induced by leukemia inhibitory factor were fully active (Laszlo and Nathanson, 2003) . Involvement of SFKs in IL-6-induced signalling in INA-6 cells (Figure 7a ) was confirmed by the increased IL-6-dependence of 7TD1 cells expressing kinase-deficient Hck-K269R (Figure 8a) . Combination of this dominant-negative effect of Hck-K269R and inhibition by peptide 18AD was not additive (Figure 8c) , demonstrating a common mechanism involving SFK activity. Of note, SFK have recently been shown to be involved in other hematological diseases, namely bcr-abl-induced B-lymphoblastic (Hu et al., 2004) and chronic lymphocytic (Contri et al., 2005) leukemia and identified as targets for small molecule drugs (Shah et al., 2004) .
In several cell culture systems we demonstrated a specific inhibitory potency of a myristoylated 18mer peptide for IL-6-or Epo-dependent cell growth and survival. While peptide 18AD is expected to prove useful for developing derivatives with possible applications for the treatment of MM, further studies are needed to elucidate its mode of action. spectroscopy. Stock solutions (100 mM) of the peptides were prepared in dimethyl sulfoxide (DMSO) and stored at À201C for up to 1 year. For pull down assays N-terminally biotinylated peptides were synthesized that contained the Nterminal linker sequence SGSGC (Schulze and Mann, 2004) . The SH2-binding control peptide had the sequence bio-SGSGC-EPQpYEEIPIYL (LaFevre-Bernt et al., 1998) . Fluorescence labelling of peptides is described in Supplementary methods.
DNA-constructs
Constitutively activated (Y501F) and inactive variants (K269R) of human Hck were generated by polymerase chain reaction (PCR) as described previously (Warmuth et al., 1997) and cloned into the EcoRI site of a pMSCV IRESwt/EGFP vector (gift from R Van Etten) as described (Warmuth et al., 2003) . For transient expression of chimeric EpoR-gp130 and Hck, constructs employing the vectors pCDNA6 and pApuro, respectively, were used (Schaeffer et al., 2001 ). (Schaeffer et al., 2001) , BaF-EH, was grown under selection by 8 mg of blasticidin/ml and 5 mg of puromycin/ml. The human myeloma cell lines MM1.S (Greenstein et al., 2003) and INA-6 (Burger et al., 2001) were gifts from ST Rosen (Northwester University, Chicago, IL, USA) and M Gramatski (Christian Albrechts University, Kiel, Germany), respectively. COS7 and 293 cells were routinely grown in DMEM supplemented with 10% fetal calf serum (FCS) and L-glutamine. Thirty hours after transfection using lipofectamine 2000 (Invitrogen) cells were deprived of FCS over night before stimulation. 7TD1 and INA-6 cells were grown in RPMI 1640 supplemented with 5% FCS, 5 pM recombinant IL-6 and 50 mM 2-mercaptoethanol. Baf-B03 cells were cultured in RPMI 1640 supplemented with 10% FCS and 10% WEHI-3B cell-conditioned medium as a source for murine IL-3.
Retroviral transduction
The generation of retroviral stocks and infection of target cells were performed as described previously (Warmuth et al., 2003) . GFP-expressing retrovirus-transduced cells were selected by flow-cytometric cell sorting on a modular flow cytometer (Cytomation Inc., Fort Collins, CO, USA).
Proliferation assay
Proliferation assays were carried out in 96-well plates by using 5-10 Â 10 3 per well of Baf-B03 or BaF-EH cells, wt 7TD1 cells or polyclonal retrovirally transduced 7TD1 populations, respectively. Two days before these experiments, cells were seeded in equal concentrations into tissue culture flasks. All assays were performed with PBS-washed cells in the growth media of 7TD1 or BaF-EH cells without antibiotic selection. Factor-dependent cell lines were stimulated with 8 U/ml of rmEpo, 5 U/ml of rmIL-3 or 80 pg/ml rhIL-6, as applicable and unless indicated otherwise. After incubation for 72 or 96 h at 371C, the proliferation was assessed by microscopic cell counting after Trypan blue staining. IC 50 values were calculated by linear interpolation. Error bars indicate s.e. of the means from triplicates. Significance thresholds of growth inhibition were determined by two-tailed Student's t-test.
Flow cytometry
The percentages of apoptotic cells and the cellular DNA content for cell cycle analysis were determined after staining with PE-labelled Annexin-V or propidium iodide, respectively, using an Epics MCL4 (Beckman Coulter, Miami, FL, USA).
Western blot analysis, IP and kinase assay Preparation of cell lysates and Western blot analysis were performed as described previously (Schaeffer et al., 2001) . Before IP experiments, 2 Â 10 7 7TD1 cells per sample were starved by serum deprivation for 20 h. Stimulation by 1 ngIL-6/ml was performed for 15 min in 1 ml of medium. For each sample 30 ml of swollen protein G-agarose suspension were pre-incubated with 2-3 mg of anti-mouse-Hck-antibody M28, anti-V5 or a 1:1 mixture of PY99 and 4G10 at room temperature for 10 min. Precleared lysate (200 ml) containing 500 mg of protein were added to the antibody-coated protein G agarose and incubated for 1-2 h at 41C on an overhead rotator. Protein G-immuno-complexes were pelleted by centrifugation at 1000 g at 41C for 15 s and washed three times with ice-cold lysis buffer. After being boiled in 4 Â sample buffer, the agarose beads were pelleted, and the eluates were analysed by Western blotting. For immunocomplex kinase assays INA-6 cells were subjected to the stimulation, lysis and IP procedures described above with the following alterations: The incubation with IL-6 was extended to 1 h and cells were washed in PBS containing 1 mM sodium orthovanadate before lysis and IP. For the phosphorylation reaction in 20 ml of kinase assay buffer (50 mM Tris HCl pH 7.2, 10 mM MgCl 2 , 2 mM dithiothreitol (DTT), 0.01 % Tween 20), 100 mM of ATP and 0.5 mg/ml of acid-inactivated rabbit muscle enolase were added to washed SFK-IPs and incubated for 15 min at 301C. For peptide competition analyses up to 150 nmol of peptide was added to the IP-reaction in a volume of 200 ml (Schulze and Mann, 2004) . The public domain program Image J was used for determinations of signal strengths by densitometry.
